There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well [...]
One of the newer drugs and one that has recently had great air play is the bone targeting radiopharmaceutical drug radium-223 or Xofigo. Currently, it is approved for men with castrate resistant prostate cancer with bone metastases. The problem is that currently Xofigo is only approved for one round of treatment using 6 monthly infusions. [...]
Prostate cancer tends to metastasize to bones as opposed to soft tissue and other organs. We have no idea why it does have a preference for bone, but it does. Developing bone metastases in prostrate cancer is a very strong negative prognostic indicator. Prostate cancer’s tendency to favor bone over soft tissue causes significant morbidity [...]
There are many different types of drugs used for hormone therapy in the treatment of prostate cancer. One of the newer classes of drugs include the GnRH antagonists. Degarelix (aka Firmagon) is the one drug in this class that is currently approved for prostate cancer. Degarelix, like the other hormone therapy drugs, was developed to [...]
Chemotherapy with Taxotere (docetaxel) might not be considered because the side effects are misunderstood. Individual experiences and side effects differ widely from one man to another. n Generally, chemotherapy is not as toxic as we think. Even if a patient feels that his chemotherapy is causing more grief than relief, it can be discontinued; there [...]
We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with non-visceral metastases. The important question we need to understand is what, of our currently available treatments, might be effective for this more aggressive and deadly type of prostate cancer? Results of the phase 3 AFFIRM [...]
You have been diagnosed with advanced or metastatic prostate cancer. It is a shock, you have cancer and your cancer has already spread outside of the prostate gland. Your doctor might have already told you that at this stage it is no longer curable, and technically it can be called terminal! That is a lot [...]
Post-radiation hematuria (PRH), or blood clots in the urine sometimes accompanied with bladder pain or pain in the back, has been a common side effect of radiation delivered to the pelvis. This type of radiation treatment is common as a primary prostate cancer treatment as well as for men who have a prostate cancer recurrence [...]
Again and again I have mentioned the huge need we have for the development of reliable bio-markers. Reliable bio-markers will allow us to know which men will respond positively to a treatment (also those who will not) and when a treatment is still effective (also when it no longer is effective). These biomarkers really don’t [...]
Being able to make better decisions about drug sequencing and combinations has become one of the current hot topics in prostate cancer research. Given that we have a number of newer drugs to use this is an important clinical issue as we make important treatment decisions. Making these clinical decisions is tough. The fact is [...]
